

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

Pfeiffer

RRID:CVCL_3326

Type: Cell Line

Proper Citation

RRID:CVCL_3326

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3326

Proper Citation: RRID:CVCL_3326

Description: Cell line Pfeiffer is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:10485273](#), [PMID:19278952](#), [PMID:19358282](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:20889926](#), [PMID:22460905](#), [PMID:23292937](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31638226](#)

Comments: Characteristics: Produces IgG kappa (ATCC=CRL-2632)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Pfeiffer

Synonyms: PFEIFFER

Cross References: BTO:BTO_0006364, CLO:CLO_0008423, EFO:EFO_0006472, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-2632, BioGRID_ORCS_Cell_line:743, BioSample:SAMN03471758, BioSample:SAMN10988533, cancercellines:CVCL_3326, Cell_Model_Passport:SIDM01775, ChEMBL-Cells:ChEMBL4295442, ChEMBL-Targets:ChEMBL4296489, Cosmic:1670184, Cosmic:1714155, Cosmic:1945187,

Cosmic:2276336, Cosmic:2437318, DepMap:ACH-000140, EGA:EGAS00001000610, GEO:GSM380141, GEO:GSM552461, GEO:GSM887514, GEO:GSM888596, GEO:GSM1035334, GEO:GSM3150252, IGRhCellID:Pfeiffer, LiGeA:CCL_851, LINCS_LDP:LCL-1122, PharmacDB:Pfeiffer_1263_2019, PRIDE:PXD012087, Progenetix:CVCL_3326, PubChem_Cell_line:CVCL_3326, Wikidata:Q54947249

ID: CVCL_3326

Record Creation Time: 20220427T221430+0000

Record Last Update: 20260920T005458+0000

Ratings and Alerts

No rating or validation information has been found for Pfeiffer.

No alerts have been found for Pfeiffer.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wang B, et al. (2026) Axes of biological variation in diffuse large B cell lymphoma. Cancer cell.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. Cancer research communications, 4(5), 1328.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF- κ B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling : CCS, 22(1), 415.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. *Molecular cancer therapeutics*, 23(5), 683.

Toh J, et al. (2024) Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. *Cell reports. Medicine*, 5(12), 101851.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Biggi AFB, et al. (2022) The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers. *Biomolecules*, 12(3).

Drosos Y, et al. (2022) NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. *Molecular cell*, 82(13), 2472.

Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. *Science advances*, 8(39), eabq0117.

Kim J, et al. (2022) KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells. *Cell reports*, 40(3), 111077.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. *Cell chemical biology*, 27(5), 538.

Potjewyd F, et al. (2020) Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degradator. *Cell chemical biology*, 27(1), 47.